NA
FBLG icon

NewEdge Advisors’s FibroBiologics FBLG Stock Holding History

NewEdge Advisors’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-845
Closed -$1.11K – 4411
2026
Q1 		$1.11K Hold
845
– – ﹤0.01% 3891
2025
Q4 		$3.8K Hold
845
– – ﹤0.01% 3745
2025
Q3 		$9.23K Sell
845
-300
-26% -$3.59K ﹤0.01% 3351
2025
Q2 		$14.3K Hold
1,145
– – ﹤0.01% 3071
2025
Q1 		$20.6K Sell
1,145
-150
-12% -$4.29K ﹤0.01% 2851
2024
Q4 		$51.8K Hold
1,295
– – ﹤0.01% 2515
2024
Q3 		$80K Buy
1,295
+150
+13% +$9.97K ﹤0.01% 2269
2024
Q2 		$114K Buy
1,145
+250
+28% +$47.7K ﹤0.01% 2081
2024
Q1 		$194K Buy
+895
New +$215K ﹤0.01% 1854

Other funds holding FBLG

CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

NewEdge Advisors's FBLG Position: Q2 2026 in Review

NewEdge Advisors sold out of FibroBiologics (FBLG) in Q2 2026, closing a stake of 845 shares — an estimated $1.11K sold.

NewEdge Advisors first reported a position in FBLG in Q1 2024 and held it in 9 quarters. The position peaked at $194K in Q1 2024. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

  • NewEdge Advisors reported no remaining FibroBiologics position as of Q2 2026 after selling out during the quarter.
  • NewEdge Advisors sold 845 FibroBiologics shares in Q2 2026, an estimated $1.11K.
  • NewEdge Advisors first reported a position in FibroBiologics in Q1 2024 and held it in 9 quarters.
  • NewEdge Advisors's FibroBiologics position peaked at $194K in Q1 2024.
  • 16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.